TISSUE MICROARRAY COLLECTIONS
Renal cell carcinoma tissue microarrays & FFPE blocks
Explore renal cell carcinoma arrays with selected survival and immunotherapy-follow-up records. Check whether pre/post-treatment groups are donor matched. For FFPE blocks, share your tissue and study requirements with our team.
THE ARRAYS
Renal cell carcinoma arrays (3)
Collection types in this TMA catalog
Explore the tissue composition and sampling groups represented in these arrays.
Primary RCC with Nivolumab (IO) treatment follow up information (TA4345
- Approx. cores
- 28
- Approx. donors
- 14
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Not listed
RCC with IO (Pembro/Nivo) follow up data, pre treatment and post IO treatment (not donor matched)
- Approx. cores
- 20
- Approx. donors
- 20
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
Renal Cell Carcinoma (RCC) with survival data (TA2880)
- Approx. cores
- 60
- Approx. donors
- 60
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Not listed
No arrays match these filters
Try another search or clear the filters to see this collection.
Data labels reflect the catalog record. Review each product and datasheet for case-level coverage. Array counts do not indicate stock availability.
FFPE TISSUE BLOCKS
Renal cell carcinoma FFPE blocks for your study
Renal FFPE profiles include clear-cell renal cell carcinoma, advanced or metastatic disease and before or after immunotherapy.
FFPE blocks are requested by inquiry. Our team confirms tissue availability, donor matching and data coverage for your study.
SELECTING YOUR ARRAY
Selecting renal cell carcinoma tissue for your study
Compare the represented tissue and the available records before choosing an array. These examples describe individual catalog entries; data coverage is specific to each array.
RCC TMA: Immunotherapy Follow-up
This renal cell carcinoma tissue microarray includes pre-treatment and post-immunotherapy samples with pembrolizumab/nivolumab follow-up data. The pre- and post-treatment groups are not donor matched.
Renal Cell Carcinoma TMA: Survival
This renal cell carcinoma tissue microarray is listed with survival data. Its survival records are a specific selection feature alongside the array's core and donor specifications.
Renal Cell Carcinoma TMA: Nivolumab Follow-up
This primary renal cell carcinoma tissue microarray is listed with nivolumab immunotherapy follow-up information. Nivolumab treatment is the specific clinical context identified for this collection.